Single Biggest Cancer Dictionary in the World
What is diacylglycerol kinase zeta inhibitor BGB-30813?
Pronunciation: /diacylglycerol* kinase* ˈzeɪtə ˌɪnˈhɪbətər bgb* ˈθərˌdi ˈθaʊzənd, eɪt ˈhənərd ənd ˈθərˈtin/
diacylglycerol kinase zeta inhibitor BGB-30813
Definition
An orally bioavailable inhibitor of diacylglycerol kinase zeta (DGKzeta), with potential antineoplastic activity. Upon oral administration, DGKzeta inhibitor BGB-30813 inhibits the activity of DGKzeta. This prevents the phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PA), and modulates the DGKzeta-regulated cellular signaling pathways. This may inhibit the proliferation of tumor cells in which DGKzeta is overactivated. DGKzeta is overexpressed in certain cancer cells and plays an important role in tumor cell survival. DGKzeta may also play a key role in tumor immunosuppression.